The article in Acta Pharmaceutica Sinica B discusses how a molecular glue called LXH-3-71 triggers the degradation of PHGDH by enhancing the interaction between DDB1 and PHGDH, affecting cancer stem cells. Targeting cancer stem cells has become important in cancer therapy, with PHGDH playing a significant role. LXH-3-71 was found to induce degradation of PHGDH in colorectal cancer cells, highlighting a potential therapeutic strategy. The compound also serves as a ligand for the DDB1-CRL E3 ligase, allowing the development of new PROTAC molecules targeting EGFR and CDK4 degradation, suggesting a promising avenue for cancer treatment.
Source link
Optimized nanoadjuvants enhance in situ tumor vaccine for ovarian cancer
